当前位置:首页 >财报库 > 报告详情

Tempus AI, Inc(TEM)美股招股说明书 S-1 (2024-06-13修订版)(英文版)(333页).pdf

上传人: 1539****815 编号:897348 2024-06-13 333页 15.37MB

1、S-1/A 1 d221145ds1a.htm S-1/ATable of ContentsAs filed with the Securities and Exchange Commission on June 13,2024Registration No.333-279558UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549Amendment No.2toFORM S-1REGISTRATION STATEMENTUNDERTHE SECURITIES ACT OF 1933Tempus AI,Inc.(E

2、xact name of Registrant as specified in its charter)Delaware 7370 47-4903308(State or other jurisdiction ofincorporation or organization)(Primary Standard IndustrialClassification Code Number)(I.R.S.EmployerIdentification Number)600 West Chicago Avenue,Suite 510Chicago,Illinois 60654(800)976-5448(Ad

3、dress,including zip code,and telephone number,includingarea code,of Registrants principal executive offices)Eric LefkofskyChief Executive Officer,Founder and ChairmanTempus AI,Inc.600 West Chicago Avenue,Suite 510Chicago,Illinois 60654(800)976-5448(Name,address,including zip code,and telephone numbe

4、r,includingarea code,of agent for service)Copies to:Eric JensenChristina T.RoupasCourtney M.W.TygessonRichard SegalLi PengliCooley LLP110 N.Wacker Drive,Suite 4200Chicago,Illinois 60606(312)881-6500 Erik PhelpsJames RogersAndrew PolovinTempus AI,Inc.600 West Chicago Avenue,Suite 510Chicago,Illinois

5、60654(800)976-5448 Alan F.DenenbergYasin KeshvargarDavis Polk&Wardwell LLP1600 El Camino RealMenlo Park,California 94025(650)752-2000Approximate date of commencement of proposed sale to the public:As soon as practicable after this registration statement is declared effective.If any of the securities

6、 being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933,check the following box.If this Form is filed to register additional securities for an offering pursuant to Rule 462(b)under the Securities Act,check the following

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
- Tempus AI, Inc. 正在通过其Tempus平台,利用人工智能(AI)在医疗保健领域实现精准医疗。 - 该平台结合了数据收集、处理和AI分析,旨在通过连接实验室结果与患者临床数据,实现个性化诊断。 - Tempus提供三个主要产品线:基因组学、数据和服务的解决方案,以及AI应用。 - 基因组学产品线包括NGS诊断和分子基因分型,2023年收入为3.63亿美元。 - 数据和服务的解决方案通过Insights和Trials产品,为生物制药公司提供数据和分析服务,2023年收入为1.688亿美元。 - AI应用产品线,包括Next平台和其他算法,旨在通过AI识别患者并优化治疗,2023年收入为550万美元。 - Tempus拥有超过5.6百万份去识别化患者记录,包括约13亿页临床文本,用于训练其AI模型。 - Tempus计划通过其平台扩展到更多疾病领域,并利用其数据优势开发生成式AI应用。
"AI医疗革命,Tempus AI如何引领?" "精准医疗新纪元,Tempus AI平台揭秘!" "Tempus AI,如何用AI改变癌症治疗?"
客服
商务合作
小程序
服务号
折叠